

Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Date: 11/05/2022

Ref: 21-22 641

Dear Sir or Madam,

Freedom of Information request

Firstly, please accept our sincere apologies in our delay in responding to you.

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 15/03/2022. Please see responses to your requests below.

1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

Treatment	Patients
CAPOX (Capecitabine with Oxaliplatin)	0
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)	<4
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Any other systemic anti-cancer therapy	6
Palliative care only	<4

We are unable to provide precise figures when these are four or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

Treatments	Patients
------------	----------

Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)	5
Nivolumab monotherapy	<4
Nivolumab and Ipilimumab	0
Any other systemic anti-cancer therapy	45
Palliative care only	<4

3. Of the Oesophageal Cancer patients (from Q2) treated with Pembrolizumab in the past 3 months, how many patients were treated for:

There are zero patients treated with Pembrolizumab a per question 2, therefore this question is not applicable.

4. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

Treatment	Patients
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)	0
Nivolumab monotherapy	0
Nivolumab and Ipilimumab	0
Any other systemic anti-cancer therapy	0
Palliative care only	0

5. Of the advanced/metastatic oesophageal cancer patients (from Q4) treated in the past 3 months, how many patients were treated for:

There are zero patients treated in question 4, therefore this question is not applicable.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team

Working together To drive excellence in care for our patients and communities